Taking a Liquid Biopsy from Lab to Clinic: What It Takes to Get Ready for Prime Time
Daniel Hayes,
Clinical Director,
University of Michigan
A tumor biomarker liquid biopsy test, is not just an assay for
circulating proteins, tumor cells, or cell free DNA. Rather, it is a
precisely developed assay that has high analytical validity and clinical
utility for a specific use context. Clinical utility requires
consideration of several factors and the generation of high levels of
evidence that use of the assay, compared to not having the results at
all, improves patient outcomes – preferably either quality or quantity
of life. These issues will be discussed in the presentation.
|
|
